Long-Term Effectiveness of Tofacitinib in Rheumatoid Arthritis
Rheumatology Day Hospital and Outpatient Clinic, ASL CN1, Cuneo, Italy
2024
n=213
publication
10 minutes
Evidence: moderate
Marta Priora, Andracco R., Eleonora Celletti, Myriam Di Penta, Alberto Lo Gullo, Marino Paroli, Elena Bravi, Romina Andracco, Valeria Nucera, Francesca Ometto, Federica Lumetti, Antonella Farina, Patrizia Del Medico, Matteo Colina, Viviana Ravagnani, Palma Scolieri, Maddalena Larosa, Elisa Visalli, Olga Addimanda, Rosetta Vitetta, Alessandro Volpe, Alessandra Bezzi, Francesco Girelli, Aldo Biagio Molica Colella, Rosalba Caccavale, Eleonora Di Donato, Giuditta Adorni, Daniele Santilli, Gianluca Lucchini, Eugenio Arrigoni, Emanuela Sabatini, Ilaria Platè, Natalia Mansueto, Aurora Ianniello, Enrico Fusaro, Maria Chiara Ditto, Vincenzo Bruzzese, Dario Camellino, Gerolamo Bianchi, Francesca Serale, Rosario Foti, Giorgio Amato, Francesco De Lucia, Ylenia Dal Bosco, Roberta Foti, Massimo Reta, Alessia Fiorenza, Guido Rovera, Antonio Marchetta, Maria Cristina Focherini, Fabio Mascella, Simone Bernardi, Gilda Sandri, Dilia Giuggioli, Carlo Salvarani, Veronica Franchina, Francesco Molica, Giulio Ferrero, Alarico Ariani, Simone Parisi
Title
Long-Term Effectiveness of Tofacitinib in Rheumatoid Arthritis
Hypothesis
What are the long-term effectiveness and predictors of response to Tofacitinib in rheumatoid arthritis patients with different cardiovascular risk profiles?
Conclusion
Tofacitinib is effective in reducing disease activity in rheumatoid arthritis patients, regardless of their cardiovascular risk status.